MedPath

Efficacy of Repyflec Cognitive Remediation Group Training in Schizophrenia

Phase 4
Completed
Conditions
Indication for Modification of Patient Cognitive Status
Interventions
Behavioral: Repyflec cognitive remediation training
Registration Number
NCT01279070
Lead Sponsor
Fundació Sant Joan de Déu
Brief Summary

The purpose of this study was to develop an integrative intervention for schizophrenia taking into account previous efficacious therapies. Thus, our aim was to evaluate the efficacy of our cognitive remediation group training: Problem Solving and Cognitive Flexibility training (REPYFLEC), focused to improve neurocognition and functioning in schizophrenia patients. We hypothesized that training executive function and metacognition would allow us to achieve improvements in neurocognition, functioning and psychiatric symptoms of patients with schizophrenia.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
62
Inclusion Criteria
  • Diagnosis of schizophrenia or schizoaffective disorder
  • More than 2 years illness duration
  • Literate
  • Mini Mental Status Examination score over 24
  • Global Assessment of Functioning scores between 40 and 70
Exclusion Criteria
  • Current acute illness exacerbation
  • Mental Retardation
  • Neurological disorder which impairs cognition
  • Currently participating in social skills training or cognitive remediation
  • Change of antipsychotic medication one month before the trial or during the 40 study weeks
  • Diagnosis of alcohol or drug dependence within 6 months of trial commencement.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
REPYFLEC cognitive remediation trainingRepyflec cognitive remediation trainingREPYFLEC cognitive remediation as a Problem solving and Cognitive flexibility group training.
Leisure groupRepyflec cognitive remediation trainingLeisure group is a stimulating activity focused on socialization through group dynamics, board games, "coffee and talk".
Primary Outcome Measures
NameTimeMethod
Executive FunctionChange from baseline in executive functioning at 40 weeks

Behavioral Assessment of the Dysexecutive Syndrome (BADS) (Wilson et al., 1996). This scale evaluates cognitive flexibility, inhibition of impulsive responses, planning and organization, working memory and time-estimation capacity. All subscales (Rule shift cards, Action Program, Key search, Temporal judgement, Zoo map and Six elements) were administered. We used subscales raw scores which run from 0 to 4. The subscales' raw score is summarized and converted to standardized total score which run (min.

12-max. 129). A higher score indicates better performance.

Secondary Outcome Measures
NameTimeMethod
Psychosocial FunctioningChange from baseline in social functioning scales at 40 weeks

The Spanish validation of the Life Skills Profile (LSP)was used. This scale measures functionality in daily life activities such as self-care, social behavior and autonomy. Raw scoring was used for the various subscales which are summarized for the total (min. 39-max. 156) with a higher score indicating a better result.

The 5 subscales are: Self-care, Non-turbulence, Social contact, Communication and Responsibility. We used the Spanish validation of the Social Functioning Scale (SFS)for measuring social behavior and relationships, autonomy, employment-occupation and leisure. Raw scoring was used for each subscale and for total score (min. 0-max. 223) with a higher score indicating a better result. All 7 subscales were administered: social engagement/ withdrawal, interpersonal behavior, independence-competence, independence-performance, pro-social activities, recreation and employment/ occupation.

Psychiatric SymptomsChange from baseline in psychiatric symptoms scales at 40 weeks

The Spanish validation of the Positive and Negative Syndrome Scale (PANSS) was used for measuring positive, negative and general symptomatology. Total raw scoring obtained through the sum of the raw scores for each subscale was considered (min. 30-max. 210) with a score of 30 representing an absence of psychiatric symptoms.

Trial Locations

Locations (1)

Parc Sanitari Sant Joan de Déu

🇪🇸

Sant Boi de Llobregat, Barcelona, Spain

© Copyright 2025. All Rights Reserved by MedPath